SuperworthCVRx price to book ratio CVRX
Market value divided by the book value of the company's net assets, since 2021.
- Today, Oct 23, 2026
- 1.9×
- 5-year median
- 3.3×
- Against its 5-year history
- 23rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 0.7× to 7.9×
- Peer median
- 2.6×
CVRx's price to book ratio is 1.9× as of Oct 23, 2026.
That is below its 5-year median of 3.3×, lower than on 77% of days in the last 5 years.
Over that time it ranged from 0.7× in Apr 2022 to 7.9× in Dec 2023.
The median for 6 medical instruments and supplies stocks of a similar size is 2.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.9× | 1.7× | 6.0× |
| 2025 | 4.0× | 1.8× | 6.6× |
| 2024 | 4.9× | 2.0× | 7.4× |
| 2023 | 7.9× | 1.7× | 7.9× |
| 2022 | 3.2× | 0.7× | 3.2× |
| 2021 | 1.6× | 1.4× | 2.4× |
Against its peers
Companies in Medical - Instruments & Supplies nearest CVRx's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| CVRXCVRx | 1.9× |
| NEPHNephros | 3.2× |
| APTAlpha Pro Tech | 0.9× |
| KEQUKewaunee Scientific | 1.3× |
| PDEXPro DEX | 4.2× |
| UTMDUtah Medical Products | 1.9× |
| INFUInfuSystem | 4.7× |
| Peer median | 2.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on CVRx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.